Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors

被引:4
|
作者
Yi, Min [1 ]
Lin, Heather [2 ]
Bedrosian, Isabelle [1 ]
Shen, Yu [2 ]
Hunt, Kelly K. [1 ]
Chavez-MacGregor, Mariana [3 ,4 ]
King, Tari A. [5 ,6 ]
Mittendorf, Elizabeth A. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
关键词
SURVIVAL; VALIDATION; BURDEN;
D O I
10.1245/s10434-019-07983-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The American Joint Committee on Cancer (AJCC) breast cancer pathological prognostic stage, which incorporates biologic factors, was developed using data from patients undergoing upfront surgery, and its application in patients receiving neoadjuvant chemotherapy (NAC) is unknown. We previously developed the Neo-Bioscore, incorporating clinical and pathological TNM categories with biologic factors, to improve the prognostic stratification of NAC patients. Objective. This study was undertaken to evaluate the use of available staging models incorporating biologic factors in NAC patients. Methods. Patients treated with NAC between 2005 and 2012 at MD Anderson (n = 2363) were staged using the Neo-Bioscore and the AJCC 8th edition: (1) clinical anatomic stage; (2) pathological anatomic stage; (3) clinical prognostic stage; and (4) pathological prognostic stage. Five-year disease-specific survival (DSS) and overall survival (OS) rates, along with Harrell's concordance index (C-index), were estimated. A National Cancer Database (NCDB) cohort (n = 12,887) treated with NAC between 2010 and 2013 was used for validation. Results. In the MD Anderson cohort, staging systems incorporating biologic factors better predicted DSS (bias-corrected C-index: pathological prognostic stage = 0.8026; Neo-Bioscore = 0.7483) and OS (bias-corrected C-index: pathological prognostic stage = 0.7780; Neo-Bioscore = 0.7260) than those using anatomic factors only. Similar results were seen in the NCDB cohort. In pairwise comparisons, the pathological prognostic stage was significantly better (p < 0.0001) than other staging systems in all comparisons except for OS in the NCDB cohort, where it was not significantly different than the Neo-Bioscore (p = 0.2). Conclusion. Biologic factors are important for determining prognosis in patients receiving NAC. These data indicate that the 8th edition AJCC pathological prognostic stage is applicable in these patients.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [41] Biodynamic response prediction in breast cancer patients receiving neoadjuvant chemotherapy.
    Morgan, Travis
    Whitacre, Eric
    Burak, William
    Manahan, Eric
    Goedde, Timothy
    Greenspan, Andrew
    Woods, John
    Nolte, David
    Turek, John
    Loesch, David M.
    An, Ran
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy
    Ma, Youzhao
    Lv, Minhao
    Yuan, Peng
    Chen, Xiuchun
    Liu, Zhenzhen
    BMC CANCER, 2023, 23 (01)
  • [43] Surgical considerations in locally advanced breast cancer patients receiving neoadjuvant chemotherapy
    Arnaout, Angel
    Boileau, Jean-Francois
    Brackstone, Muriel
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2014, 8 (01) : 39 - 45
  • [44] Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer
    Morrow, Monica
    JAMA ONCOLOGY, 2016, 2 (04) : 516 - 517
  • [45] Immune Changes in Patients with Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
    Cabloglu, N.
    Muslumanoglu, M.
    Tutuncu, Y.
    Adin-Cinar, S.
    Gurel, N.
    Kiran, B.
    Igci, A.
    Ozmen, V
    Dagoglu, T.
    Aydiner, A.
    Deniz, G.
    TURKISH JOURNAL OF IMMUNOLOGY, 2008, 13 (01): : 15 - 20
  • [46] Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
    Cao, Maria D.
    Giskeodegard, Guro F.
    Bathen, Tone F.
    Sitter, Beathe
    Bofin, Anna
    Lonning, Per E.
    Lundgren, Steinar
    Gribbestad, Ingrid S.
    BMC CANCER, 2012, 12
  • [47] Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy
    Eda Caliskan Yildirim
    Elif Atag
    Huseyin Salih Semiz
    Olcun Umit Unal
    Mehmet Uzun
    Suleyman Ozkan Aksoy
    Merih Guray Durak
    Aziz Karaoglu
    Scientific Reports, 15 (1)
  • [48] Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer
    Read, Rebecca L.
    Flitcroft, Kathy
    Snook, Kylie L.
    Boyle, Frances M.
    Spillane, Andrew J.
    ANZ JOURNAL OF SURGERY, 2015, 85 (05) : 315 - 320
  • [49] Analysis of Failure Risk Factors in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: A Large Cohort Retrospective Study
    Ababneh, H.
    Naoum, G. E.
    Niemierko, A.
    Taghian, A. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E295 - E295
  • [50] Modulation of Circulating Angiogenic Factors and Tumor Biology by Aerobic Training in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Jones, Lee W.
    Fels, Diane R.
    West, Miranda
    Allen, Jason D.
    Broadwater, Gloria
    Barry, William T.
    Wilke, Lee G.
    Masko, Elisabeth
    Douglas, Pamela S.
    Dash, Rajesh C.
    Povsic, Thomas J.
    Peppercorn, Jeffrey
    Marcom, P. Kelly
    Blackwell, Kimberly L.
    Kimmick, Gretchen
    Turkington, Timothy G.
    Dewhirst, Mark W.
    CANCER PREVENTION RESEARCH, 2013, 6 (09) : 925 - 937